EP0906099A4 - Methode de traitement du cancer - Google Patents

Methode de traitement du cancer

Info

Publication number
EP0906099A4
EP0906099A4 EP97921085A EP97921085A EP0906099A4 EP 0906099 A4 EP0906099 A4 EP 0906099A4 EP 97921085 A EP97921085 A EP 97921085A EP 97921085 A EP97921085 A EP 97921085A EP 0906099 A4 EP0906099 A4 EP 0906099A4
Authority
EP
European Patent Office
Prior art keywords
treating cancer
cancer
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97921085A
Other languages
German (de)
English (en)
Other versions
EP0906099A1 (fr
Inventor
David C Heimbrook
Allen I Oliff
Steven M Stirdivant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9613599.1A external-priority patent/GB9613599D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0906099A1 publication Critical patent/EP0906099A1/fr
Publication of EP0906099A4 publication Critical patent/EP0906099A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
EP97921085A 1996-04-03 1997-03-31 Methode de traitement du cancer Withdrawn EP0906099A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1477396P 1996-04-03 1996-04-03
US14773P 1996-04-03
GBGB9613599.1A GB9613599D0 (en) 1996-06-28 1996-06-28 A method of treating cancer
GB9613599 1996-06-28
PCT/US1997/005328 WO1997036587A1 (fr) 1996-04-03 1997-03-31 Methode de traitement du cancer

Publications (2)

Publication Number Publication Date
EP0906099A1 EP0906099A1 (fr) 1999-04-07
EP0906099A4 true EP0906099A4 (fr) 2001-02-07

Family

ID=26309586

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97921085A Withdrawn EP0906099A4 (fr) 1996-04-03 1997-03-31 Methode de traitement du cancer

Country Status (5)

Country Link
EP (1) EP0906099A4 (fr)
JP (1) JP2000504023A (fr)
AU (1) AU727939B2 (fr)
CA (1) CA2250232A1 (fr)
WO (1) WO1997036587A1 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
EP0956018A4 (fr) 1996-08-21 2000-01-12 Smithkline Beecham Corp Composes d'imidazole, compositions les contenant et leur utilisation
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
JP2002505690A (ja) 1997-06-19 2002-02-19 スミスクライン・ビーチャム・コーポレイション 新規なアリールオキシピリミジン置換イミダゾール化合物
WO1999001452A1 (fr) 1997-07-02 1999-01-14 Smithkline Beecham Corporation Nouveaux imidazoles cycloalkyle-substitues
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
WO1999017776A1 (fr) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Nouveaux composes substitues de cycloalcenyle
AR017219A1 (es) 1997-12-19 2001-08-22 Smithkline Beecham Corp Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
ES2185307T3 (es) * 1998-02-02 2003-04-16 Lg Chemical Ltd Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion.
CN1548436A (zh) 1998-05-22 2004-11-24 ʷ��˿�������ȳ�ķ���޹�˾ 新的2-烷基取代咪唑化合物
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
GB9812523D0 (en) * 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
FR2780892B1 (fr) * 1998-07-08 2001-08-17 Sod Conseils Rech Applic Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
AU6256499A (en) * 1998-09-24 2000-04-10 Merck & Co., Inc. A method of treating cancer
ATE258055T1 (de) 1998-11-04 2004-02-15 Smithkline Beecham Corp Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
US6358956B1 (en) * 1999-03-03 2002-03-19 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
PL355912A1 (en) 1999-11-22 2004-05-31 Smithkline Beecham Plc. Novel compounds
AU1783201A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
ES2249309T3 (es) 1999-11-23 2006-04-01 Smithkline Beecham Corp Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
WO2002024680A1 (fr) 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Derives d'imidazole en tant qu'inhibiteurs de la raf kinase
AU2002223571A1 (en) * 2000-09-29 2002-04-08 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit, Gmbh Pharmaceutical compositions comprising polynucleotides encoding a raf protein
CA2424797C (fr) 2000-10-05 2009-12-29 George Q. Daley Methodes d'induction de l'apoptose de cellules cancereuses et de la regression de tumeurs
JP2005505562A (ja) * 2001-09-05 2005-02-24 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｒａｆキナーゼ阻害剤としてのピリジルフランおよびピロール
GB0121488D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
AU2002365899B2 (en) * 2001-12-04 2007-09-13 Onyx Pharmaceuticals, Inc. RAF-MEK-ERK pathway inhibitors to treat cancer
ES2278170T3 (es) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
US6878731B2 (en) * 2002-08-14 2005-04-12 Pure World Botanicals, Inc. Imidazole alkaloids from Lepidium meyenii and methods of usage
CN1688194B (zh) 2002-08-19 2010-06-23 劳洛斯治疗公司 2,4,5-三取代的咪唑及其作为抗菌剂的用途
WO2004041210A2 (fr) 2002-11-05 2004-05-21 Smithkline Beecham Corporation Agents antibacteriens
US7902192B2 (en) 2003-05-15 2011-03-08 Arqule, Inc. Inhibitors of P38 and methods of using the same
CA2540518A1 (fr) * 2003-10-02 2005-04-07 Irm Llc Composes et compositions utiles comme inhibiteurs de la proteine kinase
DK1692113T3 (en) 2003-11-14 2018-01-08 Lorus Therapeutics Inc ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES
US7829560B2 (en) 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
EP1809636A1 (fr) 2004-10-19 2007-07-25 Arqule, Inc. Synthese d'inhibiteurs d'imidazo-oxazole et d'imidazothiazole de la map kinase p38
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CA2611032C (fr) 2005-05-25 2012-01-17 Genesense Technologies Inc. Derives de 2-indolyl imidazo[4,5-d]phenanthroline et utilisation dans le traitement du cancer
PT3184526T (pt) 2005-12-13 2018-12-19 Incyte Holdings Corp Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus
TWI404716B (zh) * 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
US20080312259A1 (en) 2007-06-13 2008-12-18 Incyte Corporation SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
EP2346495B2 (fr) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Formulation pharmaceutique 514
CN106967070A (zh) 2009-05-22 2017-07-21 因塞特控股公司 作为jak抑制剂的化合物
ES2487542T3 (es) 2009-05-22 2014-08-21 Incyte Corporation Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
TWI766281B (zh) 2010-03-10 2022-06-01 美商英塞特控股公司 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
AR083933A1 (es) 2010-11-19 2013-04-10 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
EA201490042A1 (ru) 2011-06-20 2014-10-30 Инсайт Корпорейшн Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
HUE057262T2 (hu) 2013-03-06 2022-04-28 Incyte Holdings Corp Eljárás és köztitermékek JAK inhibitor elõállítására
CN105308050A (zh) 2013-03-20 2016-02-03 艾普托斯生物科学公司 2-取代咪唑并[4,5-d]菲咯啉衍生物和其在治疗癌症中的用途
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
WO2015051304A1 (fr) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions, biomarqueurs et leur utilisation dans le traitement du cancer
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CA3081261A1 (fr) 2017-10-30 2019-05-09 Aptose Biosciences Inc. Arylimidazoles pour le traitement du cancer
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CN112105608B (zh) 2018-01-30 2023-07-14 因赛特公司 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法
AU2019245420A1 (en) 2018-03-30 2020-11-12 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022249192A1 (fr) * 2021-05-27 2022-12-01 Ramot At Tel-Aviv University Ltd. Composés suppresseurs de métastases à large spectre et leurs utilisations thérapeutiques dans des tumeurs humaines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032987A1 (fr) * 1994-05-31 1995-12-07 Isis Pharmaceuticals, Inc. MODULATION OLIGONUCLEOTIDIQUE ANTISENS DE L'EXPRESSION DU GENE raf
WO1996030343A1 (fr) * 1995-03-29 1996-10-03 Merck & Co., Inc. Inhibiteurs de farnesyl-proteine transferase
WO1997012876A1 (fr) * 1995-10-06 1997-04-10 Merck & Co., Inc. Imidazoles substitues ayant une activite anticancereuse et inhibitrice de cytokine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352705A (en) * 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032987A1 (fr) * 1994-05-31 1995-12-07 Isis Pharmaceuticals, Inc. MODULATION OLIGONUCLEOTIDIQUE ANTISENS DE L'EXPRESSION DU GENE raf
WO1996030343A1 (fr) * 1995-03-29 1996-10-03 Merck & Co., Inc. Inhibiteurs de farnesyl-proteine transferase
WO1997012876A1 (fr) * 1995-10-06 1997-04-10 Merck & Co., Inc. Imidazoles substitues ayant une activite anticancereuse et inhibitrice de cytokine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JELINEK T ET AL: "RAS-INDUCED ACTIVATION OF RAF-1 IS DEPENDENT ON TYROSINE PHOSPHORYLATION", MOLECULAR AND CELLULAR BIOLOGY,US,WASHINGTON, DC, vol. 16, no. 3, 1 March 1996 (1996-03-01), pages 1027 - 1034, XP000574029, ISSN: 0270-7306 *
KOHL N E ET AL: "PROTEIN FARNESYLTRANSFERASE INHIBITORS BLOCK THE GROWTH OF RAS-DEPENDENT TUMORS IN NUDE MICE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 91, no. 19, September 1994 (1994-09-01), pages 9141 - 9145, XP000882713, ISSN: 0027-8424 *
LANGE-CARTER C A ET AL: "A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf", SCIENCE,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,,US, vol. 260, 16 April 1993 (1993-04-16), pages 315 - 319, XP002108364, ISSN: 0036-8075 *
See also references of WO9736587A1 *

Also Published As

Publication number Publication date
CA2250232A1 (fr) 1997-10-09
AU727939B2 (en) 2001-01-04
EP0906099A1 (fr) 1999-04-07
AU2722197A (en) 1997-10-22
WO1997036587A1 (fr) 1997-10-09
JP2000504023A (ja) 2000-04-04

Similar Documents

Publication Publication Date Title
EP0906099A4 (fr) Methode de traitement du cancer
EP0973396A4 (fr) Procede de traitement du cancer
GB9801231D0 (en) A method of treating cancer
IL126203A0 (en) Method for treating pain
EP0906104A4 (fr) Procede de traitement de la douleur
AU4052897A (en) Cancer treatment method
ZA977564B (en) Method of treatment
GB9620412D0 (en) A method of treating a laminate
EP0850067A4 (fr) Procedes de traitement de cancers a l'aide de 6- 3- 1-adamantyl]-4-hydroxyphenyl]
GB9605828D0 (en) Treatment method
IL126064A0 (en) Method for treating pain
PL328964A1 (en) Acne treating method
EP0938296A4 (fr) Methode de traitement de l'alopecie
ZA973988B (en) Method of treatment
GB9618341D0 (en) Method of treatment
AU6256499A (en) A method of treating cancer
ZA976814B (en) A novel method of detecting and treating cancer.
ZA971899B (en) Method for treating insomnia
EP1019529A4 (fr) Procede pour le traitement du cancer
GB9613599D0 (en) A method of treating cancer
GB9612913D0 (en) A method of treating cancer
GB9611982D0 (en) A method of treating cancer
EP0918532A4 (fr) Nouveau procede de detection et de traitement du cancer
EP0987943A4 (fr) Nouvelle methode de detection et de traitement de cancer
GB9724331D0 (en) A method of treating cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20001227

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010307